Maitake research

In 2009, a phase I/II human trial, conducted by Memorial Sloan–Kettering Cancer Center, showed Maitake could stimulate the immune systems of breast cancer patients. Small experiments with human cancer patients, have shown Maitake can stimulate immune system cells, like NK cells. In vitro research has also shown Maitake can stimulate immune system cells. An in vivo experiment showed that Maitake could stimulate both the innate immune system and adaptive immune system. In vitro research has shown Maitake can induce apoptosis in cancer cell lines (human prostatic cancer cells, Hep 3B cells, SGC-7901 cells, murine skin carcinoma cells) as well as inhibit the growth of various types of cancer cells (canine cancer cells, bladder cancer cells). Small studies with human cancer patients, revealed a portion of the Maitake mushroom, known as the "Maitake D-fraction", possess anti-cancer activity. In vitro research demonstrated the mushroom has potential anti-metastatic properties. In 1997, the U.S. Food and Drug Administration (FDA) approved an Investigational New Drug Application for a portion of the mushroom. Research has shown Maitake has a hypoglycemic effect, and may be beneficial for the management of diabetes. The reason Maitake lowers blood sugar is due to the fact the mushroom naturally contains an alpha glucosidase inhibitor. Maitake contains antioxidants and may partially inhibit the enzyme cyclooxygenase. An experiment showed that an extract of Maitake inhibited angiogenesis via inhibition of the vascular endothelial growth factor (VEGF). Lys-N is a unique protease found in Maitake.[27] Lys-N is used for proteomics experiments due to its protein cleavage specificity.[28]